HeadaTerm<span>&trade;</span>
HeadaTerm<span>&trade;</span>
HeadaTerm<span>&trade;</span>
HeadaTerm<span>&trade;</span>

HeadaTerm

Regular price $29.00

Anti-Migraine Device

Overview

HeadaTerm is a clinically proven, safe and effective medical device worn on users' foreheads that prevents and treats primary headache, including migraine, tension headache, and cluster headache.   

Purposes

Primary headaches are debilitating conditions that are extremely common among people. Drug treatments are the popular solutions to many patients, but just like with anti-nausea drugs, there are side effects that often turn people away. 

HeadaTerm offers a drug-free treatment. 

Features

  • Clinically proven, safe to use  
  • User-friendly 
  • Intelligent control 
  • Communication with user (using buzzer)
  • Energy-efficient 
    • Long standby mode
    • Operates for over seven hours
  • Portability 
  • CE certified 

Small in Size, Big in Capacity

HeadaTerm is very small and light, making it convenient not only to use at home or at the office, but also on trips and outdoor travelling. 

Principle

Primary headaches, like migraine, are transmitted by the supraorbital nerve and the supratrochlear nerve. HeadaTerm introduces electric impulses from the user's forehead to act on these nerves and reduce the migraine signals transmitted. The device avoids any drug effects, making it appropriate a wide range of users. Every device contains 21 rounds of standard therapies, each therapy lasts 20 minutes. 

References

  • Sluka KA, Walsh D. Transcutaneous electrical nerve stimulation: basic science mechanisms and clinical effectiveness. J Pain. 2003 Apr;4(3):109-21.
  • Shealy CN. Transcutaneous electrical nerve stimulation: the treatment of choice for pain and depression. J Altern Complement Med. 2003 Oct;9(5):619-23.
  • Huang W, Kutner N, Bliwise DL. Autonomic activation in insomnia: the case for acupuncture. J Clin Sleep Med. 2011 Feb 15;7(1):95-102.
  • Kirsch DL, Nichols F. Cranial electrotherapy stimulation for treatment of anxiety, depression, and insomnia. Psychiatr Clin North Am. 2013 Mar;36(1):169-76.
  • Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013 Feb 19;80(8):697-704.

More Choices

HeadaTerm-d (Coming soon)
Smart/Data/app

Quick Start Guide